NCT05011487 Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC Status RECRUITING Phase PHASE2
NCT04988607 Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC Status UNKNOWN Phase PHASE2
NCT04959981 A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC Status COMPLETED Phase PHASE1
NCT04908956 Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) Status TERMINATED Phase PHASE2
NCT04870190 Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases Status UNKNOWN Phase PHASE3
NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT04862780 (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC Status TERMINATED Phase PHASE1
NCT04829019 Neurocognition in NSCLC Patients Treated With Osimertinib or Osimertinib + WBI Status RECRUITING Phase PHASE2
NCT04816838 A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations Status RECRUITING Phase NA
NCT04816214 Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy Status TERMINATED Phase PHASE3
NCT04780568 Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer Status RECRUITING Phase PHASE1
NCT04772235 Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients Status RECRUITING Phase PHASE1
NCT04770688 Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib Status COMPLETED Phase PHASE1/PHASE2
NCT04769388 Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04762199 MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer Status RECRUITING Phase PHASE1
NCT04743505 Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT04721015 Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT04720976 JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors Status COMPLETED Phase PHASE1/PHASE2
NCT04695925 Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations Status ACTIVE_NOT_RECRUITING Phase PHASE3